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Abstract 
Immunoglobulin G (IgG) harbors a conserved N-glycosylation site which is important for its 
effector functions. Changes in glycosylation of IgG occur in many autoimmune diseases but 
also in physiological conditions. Therefore, the glycosylation pattern of serum IgG is well 
characterized. However, limited data is available on the glycosylation pattern of IgG in 
cerebrospinal fluid (CSF) compared to serum. Here, we report significantly reduced levels of 
bisected glycans in CSF IgG. Galactosylation and sialylation of IgG4 also differed 
significantly. Therefore, we propose a common mechanism mediating glycosylation changes 
of IgG at the transition from serum to CSF in steady state conditions. 
Keywords: Glycosylation, Immunoglobulin G, Cerebrospinal fluid, Serum, Bisecting, 
Sialylation  
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1. Introduction 
All immunoglobulin G (IgG) subclasses harbor a highly conserved N-glycosylation site at 
Asparagine297 (Huber et al. , 1976). Glycosylation of IgG is known to be important for 
mediating its effector functions in vivo. It was shown that genetic or enzymatic removal of the 
sugar moiety abolishes the activity of IgG (Bohm et al. , 2014). Glycosylation starts in the 
endoplasmic reticulum, then formed oligomannose structures are trimmed and addition of 
other sugars such as fucose, galactose and sialic acid happens in the Golgi apparatus 
(Stanley et al. , 2009). Around 11 mg/ml of IgG are found in the serum of healthy human 
individuals (Cassidy and Nordby, 1975), whereas in cerebrospinal fluid (CSF) the 
concentration is only around 0.02 mg/ml (Ganrot and Laurell, 1974). IgG in CSF of healthy 
individuals is derived from the blood plasma and gains access to the ventricular and 
subarachnoid space across the blood brain barrier (Keir G., 1986). 
Since the publication of abnormal N-glycosylation patterns in context with rheumatoid arthritis 
over 30 years ago (Parekh et al. , 1985), glycosylation patterns of IgG in serum have been 
extensively researched in physiological and pathological conditions. It is now known that N-
glycosylation patterns change during acute inflammation and aging but also during 
pregnancy (Arnold et al. , 2007, Kristic et al. , 2014, Parekh et al. , 1988, van de Geijn et al. , 
2009). The first two conditions lead to a glycosylation pattern with less galactosylated IgG 
(G0) associated with increased inflammation, whereas in pregnancy galactosylated 
glycoforms (G1, G2) increase. From studies with intravenous IgG (IVIG) we know that 
antibodies with enhanced therapeutic activity show reduced affinity for most activating Fcγ 
receptors (FcγR) (Anthony et al. , 2008a, Anthony and Ravetch, 2010, Anthony et al. , 
2008b). Studies of monoclonal therapeutic antibodies revealed that enhanced antibody-
dependent cellular cytotoxicity (ADCC) results from an enhanced affinity for and better 
interaction with the activating human FcγRIIIA of antibodies lacking core fucose (Bruggeman 
et al. , 2017, Nimmerjahn and Ravetch, 2012, Sakae et al. , 2017). Subedi et al. not only 
found a decreased affinity for FcγRIIIA for fucosylated antibodies, but also for FcγRIIB, 
FcγRIIB and FcγRIIC (Subedi and Barb, 2016). Additionally, this enhanced ADCC can further 
be influenced by additional galactosylation of IgG (Subedi and Barb, 2016, Thomann et al. , 
2016, Yamaguchi et al. , 2006). 
However, most of these studies have been conducted using either monoclonal therapeutic 
antibodies or IVIG isolated from the serum of thousands of healthy donors. So far, little is 
known about the glycosylation patterns of IgG in CSF. In one study released glycans were 
investigated, which were found to be dissimilar between serum and CSF (Karlsson et al. , 
2017). Of note, the serum and CSF samples were not from the same donors. Another study 
was performed on IgG1 glycopeptides in paired CSF and serum samples from patients with 
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multiple sclerosis (MS) and healthy controls, showing altered IgG1 glycosylation patterns in 
CSF of MS patients with elevated bisecting N-acetylglucosamine (GlcNAc), afucosylation 
and reduced galactosylation that correlated with the degree of intrathecal IgG synthesis 
(Wuhrer et al. , 2015). 
Taken together, there is only little data available on the glycosylation patterns of IgG 
subclasses in the CSF compared to serum. Therefore, we herein aim to identify differences 
in the glycosylation of CSF and serum IgG subclasses of the same individual. 
2. Material and Methods 
2.1. Cohort 
Twelve patients were recruited at the department of Psychiatry at the University Hospital 
Erlangen. The patients referred to the clinic due to cognitive disturbances and received a 
diagnostic work-up comprising routine blood tests, cerebrospinal fluid (CSF) investigations 
including oligoclonal bands and neurochemical dementia diagnostics, brain-MRI, brain-
perfusion SPECT and a neuropsychological investigation with the CERAD+ battery. 
Diagnoses were made according to the revised National Institute of Neurological and 
Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related 
Disorders Association (ADRDA) criteria (Albert et al. , 2011, McKhann et al. , 2011). Only 
patients with mild cognitive impairment but without clinical and laboratory signs of 
Alzheimer’s dementia were included. Most patients suffered from an affective disorder, two 
from suspected frontotemporal lobar degeneration and one from suspected vascular disease. 
Patients with malignomas, infections or a disturbed blood brain barrier were excluded from 
the study. Also, samples were assured to be free of a contamination with blood by an 
erythrocyte count. A short characterization of the patients is included in Table 1. The study 
protocol was approved by the ethical committee of the University Hospital Erlangen (No. 
3987) and patients provided their informed written consent. 
Table 1: Characterization of the patients included in the study 
Patient ID Age at lumbar 
puncture 
Sex Diagnosis 
1 55 female MCI (probable fronto temporal lobar degeneration) 
2 60 female MCI (probable depression) 
3 85 female MCI (probable depression) 
4 75 male MCI (probable vascular disease) 
5 60 female MCI (not Alzheimer´s disease) 
6 54 female MCI (probable fronto temporal lobar degeneration) 
7 56 female MCI (probable depression) 
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8 70 female Depression 
9 64 male MCI (probable depression) 
10 51 male MCI (probable depression) 
11 71 female Bipolar disorder 
12 58 male MCI (probable depression) 
Abbreviation: MCI, mild cognitive impairment 
CSF and serum were centrifuged at 1600 g for 10 min within 2 h after sampling and stored in 
aliquots at -80°C until further use. 
2.2. Immunoglobulin G purification from serum and cerebrospinal fluid 
Immunoglobulin G (IgG) was purified using recombinant Protein G Agarose 
(ProteinMods, Madison, Wisconsin, USA). The column, containing 100 µl of Protein 
G Agarose was washed and equilibrated with 10 volumes of binding buffer (150 mM 
NaCl, 20 mM Tris-HCl, pH 7.5). The sample was diluted 1/1 with binding buffer, 
gently applied to the column (400 µl) and kept 30 min at room temperature (RT). All 
column washes/elutions were done by centrifugation at 3000 rpm. Flow-through 
fractions were collected and the column was washed with 2 ml of Tris-buffered saline 
(TBS) in 10 steps. IgG was eluted with 0.1 M glycine-HCl, pH 2.7, immediately 
neutralized by 1 M Tris-HCl, pH 9.0. Protein concentration was measured by the 
NanoDropTM 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). 
2.3. LC-ESI-MS analysis 
For the analysis of Fc-glycosylation, the IgG eluates were subjected to tryptic digest by 
adding 600 ng tosyl-phenylalanyl-chloromethyl-ketone treated trypsin (Merck KGaA, 
Darmstadt, Germany) in 40 µl ammonium bicarbonate buffer followed by overnight incubation 
at 37°C. Digested IgG was separated and analyzed on an Ultimate 3000 UHPLC system 
(Dionex Corporation) coupled to a Maxis Impact HD quadrupole-time-of-flight mass 
spectrometer (MS) (Bruker Daltonics, Bremen, Germany) as described previously with minor 
modifications (Falck et al. , 2017). Following extraction of tryptic glycopeptides by a C18 solid 
phase extraction trap column (Dionex Acclaim PepMap100), separation was achieved on an 
Ascentis Express C18 nano-liquid chromatography (LC) column (Supelco, Bellefonte, PA) 
conditioned at 900 nl/min with 0.1% TFA (mobile phase A) after which the following gradient 
of mobile phase A and 95% acetonitrile (mobile phase B) was applied: 0 min 3% B, 2 min 6% 
B, 4.5 min 18% B, 5 min 30% B, 7 min 30% B, 8 min 1% B and 11min 1% B. The UHPLC 
was interfaced to the MS with a CaptiveSpray ESI source and nanoBooster (Bruker 
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Daltonics). Mass spectra were recorded from m/z 550 to 1800 at a frequency of 1 Hz. 
Quadrupole ion energy and collision energy of the MS were set at 2 and 5 eV, respectively. 
The total analysis time per sample was 13 min.  
Quality of mass spectra was evaluated based on total signal intensities per glycopeptide 
cluster. Analyte curation was performed using the signal-to-noise ratio, isotopic pattern 
quality, and observed m/z deviation as obtained after data (pre-)processing with LacyTools 
(Jansen et al. , 2016). Included analytes and the calculation of galactosylation, sialylation 
and bisection are described in the following paragraphs (2.3.1 and 2.3.2). 
2.3.1. Detected glycopeptide compositions 
The glycosylation traits were calculated based on the glycopeptide composition in Table 2. H 
indicates the number of hexoses, N the number of N-acetylglucosamines, F the number of 
fucoses and S the number of sialic acid (N-acetylneuraminic acid). 
Table 2: Glycopeptide composition used for calculating the glycosylation traits 
IgG1 IgG2/3 IgG4 
H3N4F1 H3N4F1 H3N4F1 
H4N4F1 H4N4F1 H4N4F1 
H5N4F1 H5N4F1 H5N4F1 
H3N5F1 H3N5F1 H3N5F1 
H4N5F1 H4N5F1  
H5N5F1 H5N5F1 
 
H4N4F1S1 H4N4F1S1 
 
H5N4F1S1 H5N4F1S1 H5N4F1S1 
H4N5F1S1 
  
H5N5F1S1 
  
H5N4F1S2 
  
H3N4 
  
H4N4 
  
H5N4 
  
H4N5  
 
H5N5 
  
 
2.3.2. Calculations 
Fucosylation: SUMIF(IgGx*F*)/SUMIF(IgGx*), where x is the subclass identifier, asterisks are 
wildcards, and F indicates fucosylation. 
Galactosylation: (0.5 × SUMIF(IgGx*H4*) + SUMIF(IgGx*H5*))/SUMIF(IgGx*), where x is the 
subclass identifier, asterisks are wildcards, H4 indicates the presence of one galactose (in 
total four hexoses in the glycan), and H5 indicates the presence of two galactoses. 
Bisection: SUMIF(IgGx*N5*)/SUMIF(IgGx*), where x is the subclass identifier, asterisks are 
wildcards, and N5 indicates the presence of a bisecting GlcNAc. 
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Sialylation: (0.5 × SUMIF(IgGx*S1) + SUMIF(IgGx*S2))/SUMIF(IgGx*), where x is the 
subclass identifier, asterisks are wildcards, S1 indicates the presence of one sialic acid, and 
H5 indicates the presence of two sialic acids. 
2.4. Lectin-ELISA 
To detect the exposure of sialic acid on IgG from serum and CSF, we conducted Lectin-
ELISA as described previously (Stumer et al. , 2017). Briefly, 96-wells MaxiSorpTM microtitre 
plates (442404, Nunc, Roskilde, Denmark) were coated with 2 µg/ml F(ab’)2-fragment of goat 
anti-human IgG (109-006-003, Jackson ImmunoResearch Europe Ltd, Ely, United Kingdom) 
overnight at +4°C in coating buffer (0.1 M Na2CO3/NaHCO3, pH 9.6). After each incubation, 
the plate was washed three times with phosphate buffered saline (PBS) containing 0.05% 
Tween-20 (PBS-T) (8.22184.1000, Merck, Darmstadt, Germany). As blocking step, we used 
a special gelatin blocking buffer containing 3% deglycosylated gelatin, 0.1% CaCl2 and 0.1% 
MgCl2 for 2 hours at RT. Serum was diluted 1:5000 and CSF 1:300 in PBS-T and applied for 
1 hour at RT to the plates. After another washing step, we employed horseradish peroxidase 
(HRP) labelled goat anti-human IgG (2048-05, Southern Biotech, Birmingham, Alabama, 
USA) or IgM antibodies (2020-05, Southern Biotech) or biotinylated Sambucus nigra lectin 
(SNA) (B1305, Vector Laboratories, Burlingame, California, USA) to detect exposure of α2,6-
linked sialic acid. Pierce™ High Sensitivity Streptavidin-HRP (21130, Thermo Fisher 
Scientific) was used to detect the biotinylated SNA. Optical density was read with the Sunrise 
(Tecan, Männedorf, Switzerland) at 450 nm with a reference at 620 nm.  
2.5. Statistics 
To describe the significance of differences in one glycan between serum and corresponding 
CSF, we used paired Wilcoxon-signed rank test as normal distribution of values was not 
fulfilled. To describe the correlation of sialic acid exposure with IgG and IgM, we used 
Spearman-Rho. Significant differences in the ratio of SNA to IgG in CSF and serum was 
calculated using Wilcoxon-signed rank test. *** p < 0.001, ** p < 0.01, * p < 0.05. Statistics 
were calculated using the SPSS software (IBM Corp. Released 2012. IBM SPSS Statistics 
for Windows, Version 21.0. Armonk, NY: IBM Corp.) and GraphPad Prism version 5.00 for 
Windows (GraphPad Software, La Jolla California USA, www.graphpad.com). 
3. Results 
3.1. LC-ESI-MS analysis 
The Fc part of immunoglobulin G harbors a conserved N-glycosylation site at Asparagine297 
(Figure 1). We analyzed the glycosylation of IgG in the serum and corresponding CSF of 
twelve individuals without any diagnosed neuro-inflammatory disorder by liquid 
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chromatography electrospray ionization mass spectrometry (LC-ESI-MS) and calculated the 
relative ratio of Bisection, Galactosylation, Sialylation and Fucosylation using the 
glycopeptides depicted in Figure 1.  
 
Figure 1 N-glycosylation of Asparagine
297
 in the Fc part of immunoglobulin G with the 
glycopeptides depicted that were used for calculating the glycosylation traits. 
Oligomannose is shown as a green circle. N5 means bisecting (5 N -
acetylglucosamine, blue square). H3 is used for no galactose, H4 for 1 galactose, H5 
for 2 galactose (yellow circle), respectively. F1 means fucose (red triangle). S1 and 
S2 is used for 1 or 2 sialic acid (purple rhombus), respectively.  
For all subclasses of IgG analyzed, the level of bisection was significantly lower in CSF 
compared to serum (Figure 2). Galactosylation, sialylation and fucosylation did not differ 
significantly in CSF IgG compared to serum IgG for IgG1 and IgG2/3. However, for IgG4 
galactosylation and sialylation as well as the amount of sialic acids per galactose (SA/Gal) 
were significantly lower in CSF compared to serum IgG of the same individual. Interestingly, 
our individuals can be divided into two groups depending on total sialylation of IgG1 and 
IgG2/3. One group shows a higher sialylation in CSF compared to corresponding serum and 
the second group lower CSF sialylation. However, only one individual showed higher 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
sialylation of both IgG1 and IgG2/3, whereas for the other individuals in CSF IgG1 sialylation 
was higher as compared to serum, and IgG2/3 sialylation was lower. 
 
Figure 2 IgG glycosylation traits differ in serum vs. corresponding CSF for IgG1, IgG2/3 and IgG4. 
IgG glycosylation was quantified using liquid chromatography electrospray ionization mass 
spectrometry (LC-ESI-MS) in paired serum/CSF samples from 12 individuals. Relative abundance 
of each CSF glycosylation trait compared to corresponding serum was calculated. Lines indicate 
corresponding serum/CSF pairs. CSF samples are depicted as blue dots, serum samples as red 
dots. Gal is used as abbreviation for Galactosylation, SA for Sialylation and SA/Gal for sialic acid 
per galactose. Statistical significance was determined using Wilcoxon-signed rank test for paired 
samples. ** p < 0.01; * p < 0.05. 
3.2. Lectin-ELISA results 
Next, we wanted to know if the observed differences for overall sialylation of IgG4 correlate 
with the actual exposure of sialic acid on IgG in native conditions. Therefore, we performed 
Lectin-ELISA with Sambucus nigra lectin (SNA) that binds specifically to sialic acid α2,6-
linked to galactose if the sugar is present and accessible for binding. In both, serum and 
CSF, the binding of SNA to α2,6-linked sialic acid correlates positively and significantly with 
the detected level of IgG (Figure 3a; p = 0.00313 and 0.00015, respectively). The correlation 
between lectin binding and IgG content resulted stronger in CSF compared to serum (Figure 
3a; Spearman-Rho = 0.761 and 0.641, respectively). The presence of α2,6-linked sialic acid 
associated with IgG was significantly higher in the serum compared to CSF (Figure 3b, 
paired t test, p < 0.001). This higher binding of SNA in serum is not due to contaminating 
IgM. IgM detection correlates with IgG only in serum (Figure 3c, Spearman-Rho, p = 
0.00002) and not with SNA binding. 
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Figure 3 Exposure of sialic acid is increased in serum compared to CSF independent of 
contaminating IgM. (a) Exposure of α2,6-linked sialic acid correlates with IgG detection in serum 
and corresponding CSF samples of 19 individuals as detected by Lectin-ELISA. Optical densities 
for Sambucus nigra lectin (SNA) and IgG are depicted. CSF samples are depicted in blue circles, 
serum in red circles. Correlation was calculated using Spearman-Rho and trend lines are depicted 
in blue for CSF and red for serum. (b) SNA bound to sialic acid is higher in serum compared to CSF 
as detected by Lectin-ELISA. The ratio of SNA/IgG in serum and CSF is depicted. CSF samples 
are depicted in blue circles, serum in red circles. Significance was determined using a paired t-test. 
*** p< 0.001. (c) Detection of IgM correlates with IgG only in serum of 19 individuals as detected by 
ELISA. Optical densities for Sambucus nigra lectin (SNA) and IgG are depicted. CSF samples are 
depicted in blue circles, serum in red circles. Correlation was calculated using Spearman-Rho and 
trend lines are depicted in blue for CSF and red for serum . 
Taken together, sialylated IgG4 is not only increasingly detected in the serum compared to 
CSF but also the binding of SNA to sialic acid on IgG is higher in the serum. Additionally, 
IgG4 sialylation and galactosylation in CSF and corresponding CSF behaves differently and 
most importantly, bisecting IgG is less common in CSF IgG independent of the subclass. 
Since the most common causes of intrathecal production of IgG in our individuals were 
excluded at the start of the study, this observation might raise the question for a different 
mechanism of IgG glycan tree modification at the transition from serum to CSF. 
4. Discussion 
In this study, we detected significant differences for various glycosylation traits between 
serum and CSF of the same individual, most prominently for IgG4. IgG glycosylation traits 
calculated from individual glycans detected in serum (see 2.3.1) are in line with previous 
publications (Clerc et al. , 2016, Karlsson, Ndreu, 2017, Kristic, Vuckovic, 2014) and glycans 
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detected in CSF in our individuals are similar to previous reports (Karlsson, Ndreu, 2017, 
Wuhrer, Selman, 2015). 
Wuhrer et al. described in their study a more pro-inflammatory pattern of IgG glycosylation 
with elevated levels of bisecting N-acetylglucosamin (GlcNAc), afucosylation and reduced 
galactosylation for IgG1 in the CSF of patients with multiple sclerosis (MS) (Wuhrer, Selman, 
2015). We only detected a significantly reduced galactosylation of IgG in the CSF compared 
to corresponding serum in our donors for IgG4. However, for all IgG subclasses analyzed the 
levels of bisecting GlcNAc were reduced in the CSF, whereas fucosylation did not differ 
significantly. Additionally, the relative amount of sialic acid was reduced in CSF IgG4 
compared to serum in our cohort. 
More complex glycosylation patterns of CSF proteins compared to serum were already 
described in the 1990s and the term “brain-type glycosylation” was coined for low amounts of 
terminal sialic acid, elevated levels of bisecting GlcNAc and terminal fucosylation (Hoffmann, 
1996, Hoffmann et al. , 1995). However, this “brain-type glycosylation” is not in concordance 
with the glycosylation patterns of IgG detected in the CSF in this study. For all IgG 
subclasses, we detected lower levels of bisecting GlcNAc and no difference in fucosylation of 
IgG1. With the methods used here, we are not able to distinguish between core (a1,6-
fucosylation) and terminal (a1,2-galactose or a1,3/4-GlcNAc) fucosylation, however, to our 
knowledge, terminal fucosylation for IgG N-glycans was so far not described, indicating that 
the pathways used to synthesize glycans of IgG appearing in serum and CSF are sharing 
common glycosyltransferases. 
In general, high amounts of sialic acid and galactose are considered rather anti-inflammatory 
as reviewed in (Maverakis et al. , 2015). This speaks for a more pro-inflammatory effector 
type of IgG in CSF of our donors as we detected significantly reduced galactosylation and 
sialylation of IgG at least for IgG4 in the CSF. Additionally, the binding of the SNA lectin, 
specific for α2,6-linked sialic acid, was significantly reduced in IgG derived from CSF in our 
cohort. Whether this hyposialylation of CSF IgG has relevance for its effector functions needs 
to be further investigated. From the functional point of view, one of the main drivers for 
enhanced antibody-dependent cellular cytoxicity (ADCC) is afucosylation (Bruggeman, 
Dekkers, 2017, Nimmerjahn and Ravetch, 2012, Sakae, Satoh, 2017, Subedi and Barb, 
2016). Bisecting was also published to enhance ADCC (Umana et al. , 1999); however, it is 
not clear if the effect is due to bisecting GlcNAc alone or an accompanying afucosylation 
(Shinkawa et al. , 2003). We did not detected significantly reduced levels of total fucoslyation 
for IgG1 in the CSF compared to corresponding serum in our individuals. Additionally, to 
unleash more pro-inflammatory IgG effector functions, complement and cells that mediate 
ADCC are needed. Wuhrer et al. explained the more pro-inflammatory glycosylation pattern 
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of IgG in the CFS of patients with MS as a result of intrathecal IgG production (Wuhrer, 
Selman, 2015). The inflammatory milieu of the central nervous system in MS patients shifts 
IgG1 glycosylation towards enhanced effector functions. However, individuals with intrathecal 
IgG production were excluded at the start from our study. From the twelve subjects included 
in this study six had only a subjective cognitive impairment probably due to depression. The 
other six suffered from an objective mild cognitive impairment but had no diagnosis of 
Alzheimer’s disease or other dementia. Therefore, the intrathecally produced IgG can, in our 
case, not be responsible for the differences in glycosylation of CSF compared to serum.  
Possible explanations for the observed differences are (I) distinct IgG glycoforms are 
transported preferentially into the central nervous system (CNS), (II) clearance of CSF IgG is 
dependent on different glycosylation compared to serum IgG or (III) glycosylation of IgG is 
modified at the transition from serum to CSF. As bisected IgG was significantly less detected 
in CSF compared to serum independent of the IgG subclass, one could argue that bisection 
somehow prevents the IgG from transport into the CNS. However, for sialylation our cohort 
was divided into two groups. The first group showed a higher sialyation of IgG1 or IgG2/3 in 
CSF, the second a lower sialylation of IgG1 or IgG2/3 in CSF. Therefore, not only the glycan 
seems to influence which IgG is transported into the CNS but maybe also the subclass. 
Regarding the second possible explanation, one should mention that clearance of IgG in the 
serum is dependent on the neonatal Fc receptor (FcnR). This receptor is also expressed at 
the brain microvasculature and choroid plexus epithelium as demonstrated in rats 
(Schlachetzki et al. , 2002). However, clearance of IgG by the FcnR is independent of IgG Fc 
glycosylation and happens in a pH dependent manner (Datta-Mannan et al. , 2007, 
Roopenian and Akilesh, 2007). Unless another Fc receptor is responsible for the clearance 
of IgG from the CSF this explanation seems unlikely. 
Therefore, we propose that modification of IgG glycosylation at the transition of serum to 
CSF is at least partly responsible for the observed differences. These modifications would 
result in a lower galactosylation of IgG in CSF at least for IgG4 and maybe some of IgG1 and 
IgG2/3. However, the exact mechanism of these modifications and why not all subclasses 
are affected in the same way needs further investigations. 
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Highlights 
 Immunoglobulin G (IgG) in cerebrospinal fluid differs significantly from serum IgG 
 Cerebrospinal fluid IgG is characterized by significantly less bisected glycans 
 IgG4 derived from serum is more galactosylated and sialylated 
 Sialic acid specific Sambucus nigra lectin preferentially binds to serum IgG 
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